Similar articles for PMID: 24400126

Year	Number of Results
2012	7
2013	8
2014	12
2015	15
2016	8
2017	9
2018	17
2019	15
2020	12
2021	1
2022	1
2024	0

1

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Menzies AM, Haydu LE, Carlino MS, Azer MW, Carr PJ, Kefford RF, Long GV. Menzies AM, et al. PLoS One. 2014 Jan 6;9(1):e85004. doi: 10.1371/journal.pone.0085004. eCollection 2014. PLoS One. 2014. PMID: 24400126 Free PMC article.

2

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.

Cavalieri S, Di Guardo L, Cimminiello C, Bono A, Tolomio E, Colombetti A, Valeri B, Di Tolla G, de Braud F, Del Vecchio M. Cavalieri S, et al. Tumori. 2016 Oct 13;102(5):501-507. doi: 10.5301/tj.5000539. Epub 2016 Jul 27. Tumori. 2016. PMID: 27470608

3

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Chen G, et al. JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509. JAMA Oncol. 2016. PMID: 27124486 Free PMC article. Clinical Trial.

4

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV. Azer MW, et al. Cancer. 2014 Feb 15;120(4):530-6. doi: 10.1002/cncr.28445. Epub 2013 Nov 5. Cancer. 2014. PMID: 24496868 Free article.

5

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Long GV, et al. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16. Lancet Oncol. 2016. PMID: 27864013

6

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.

Schmitt RJ, Kreidler SM, Glueck DH, Amaria RN, Gonzalez R, Lewis K, Bagrosky BM, Kwak JJ, Koo PJ. Schmitt RJ, et al. Nucl Med Commun. 2016 Feb;37(2):122-8. doi: 10.1097/MNM.0000000000000406. Nucl Med Commun. 2016. PMID: 26440571 Free PMC article.

7

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. Sloot S, et al. Melanoma Res. 2016 Feb;26(1):83-7. doi: 10.1097/CMR.0000000000000214. Melanoma Res. 2016. PMID: 26731560

8

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF^V600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV. Dummer R, et al. Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30. Lancet Oncol. 2020. PMID: 32007138 Clinical Trial.

9

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO). Hassel JC, et al. Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20. Cancer Med. 2018. PMID: 29266761 Free PMC article.

10

Dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Davies MA, et al. Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4. Lancet Oncol. 2017. PMID: 28592387 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year